Comparative Pharmacology
Head-to-head clinical analysis: SULFADIAZINE SODIUM versus TERFONYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFADIAZINE SODIUM versus TERFONYL.
SULFADIAZINE SODIUM vs TERFONYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfadiazine is a competitive inhibitor of dihydropteroate synthase, blocking the conversion of p-aminobenzoic acid (PABA) to dihydropteroate, thereby inhibiting bacterial folic acid synthesis.
TERFONYL is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking folate synthesis and bacterial DNA replication.
2-4 g IV initially, then 1-2 g IV every 6-8 hours; oral dose: 2-4 g loading, then 1-2 g every 6 hours
2 g intravenously every 12 hours over 24 hours for susceptible infections.
None Documented
None Documented
Terminal elimination half-life: 10-20 hours (prolonged in renal impairment; context: requires dose adjustment in CrCl <50 mL/min).
Terminal elimination half-life is 2.5-4 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl < 30 mL/min).
Renal: 60-85% (via glomerular filtration and tubular secretion, with acetylation in liver reducing solubility and increasing crystalluria risk). Biliary/fecal: less than 15%. Unchanged drug and acetylated metabolites both excreted.
Renal excretion accounts for 70-90% of elimination as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal excretion constitutes 10-30%.
Category D/X
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic